Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5Gastrointestinal 3Breast 3Thoracic 2Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Stomach Neoplasms 2Weight Loss 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cachexia 1Anorexia 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Olanzapine × Gastrointestinal × Clear all
NCT07581405 2026-05-12

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

University of Illinois at Chicago

Phase 2 Not yet recruiting
26 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

NCT03575637 2018-07-03

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

Peking University

Phase 2 Unknown
180 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡